KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that key translational pharmacology studies of its lead molecule TRV027 were published on August 11th, 2011 in Circulation:Heart Failure, and that new data from another of these studies were presented at The European Society of Cardiology meeting in Paris on August 31st, 2011. Additional data on the compound will also be presented as a poster at the upcoming Heart Failure Society of America meeting in Boston, on September 19th.
